Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1978 3
1980 1
1981 2
1982 1
1983 1
1984 3
1985 2
1986 3
1987 2
1988 2
1989 3
1990 6
1991 10
1992 8
1993 5
1994 9
1995 8
1996 5
1997 6
1998 15
1999 8
2000 12
2001 11
2002 6
2003 13
2004 19
2005 17
2006 27
2007 20
2008 25
2009 26
2010 17
2011 23
2012 33
2013 28
2014 20
2015 13
2016 15
2017 23
2018 29
2019 23
2020 20
2021 23
2022 25
2023 24
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

533 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Focal segmental glomerulosclerosis 8"
Page 1
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
BACKGROUND: An unmet need exists for focal segmental glomerulosclerosis (FSGS) treatment. In an 8-week, phase 2 trial, sparsentan, a dual endothelin-angiotensin receptor antagonist, reduced proteinuria in patients with FSGS. The efficacy and saf …
BACKGROUND: An unmet need exists for focal segmental glomerulosclerosis (FSGS) treatment. In an 8-week, phase 2 …
Interventions for focal segmental glomerulosclerosis in adults.
Hodson EM, Sinha A, Cooper TE. Hodson EM, et al. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD003233. doi: 10.1002/14651858.CD003233.pub3. Cochrane Database Syst Rev. 2022. PMID: 35224732 Free PMC article. Review.
BACKGROUND: Focal segmental glomerulosclerosis (FSGS) can be separated into primary, genetic or secondary causes. ...SELECTION CRITERIA: Randomised controlled trials (RCTs) and quasi-RCTs of any intervention for FSGS in adults were included. ...
BACKGROUND: Focal segmental glomerulosclerosis (FSGS) can be separated into primary, genetic or secondary causes. ...SE …
Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.
Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants. Trimarchi H, et al. Kidney Int. 2017 May;91(5):1014-1021. doi: 10.1016/j.kint.2017.02.003. Epub 2017 Mar 22. Kidney Int. 2017. PMID: 28341274 Free article. Review.
Since the Oxford Classification of IgA nephropathy (IgAN) was published in 2009, MEST scores have been increasingly used in clinical practice. Further retrospective cohort studies have confirmed that in biopsy specimens with a minimum of 8 glomeruli, mesangial hyper …
Since the Oxford Classification of IgA nephropathy (IgAN) was published in 2009, MEST scores have been increasingly used in clinical …
Pathology of IgA nephropathy.
Roberts IS. Roberts IS. Nat Rev Nephrol. 2014 Aug;10(8):445-54. doi: 10.1038/nrneph.2014.92. Epub 2014 May 27. Nat Rev Nephrol. 2014. PMID: 24861083 Review.
Biopsy specimens meeting these diagnostic criteria have a range of histological changes that are reflected in the variable clinical course of IgA nephropathy. The impact of histology on outcomes in IgA nephropathy has been clarified in a number of large retrospective clini …
Biopsy specimens meeting these diagnostic criteria have a range of histological changes that are reflected in the variable clinical c …
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesar V, Zhdanova O, Komers R; DUET Study Group. Trachtman H, et al. J Am Soc Nephrol. 2018 Nov;29(11):2745-2754. doi: 10.1681/ASN.2018010091. J Am Soc Nephrol. 2018. PMID: 30361325 Free PMC article. Clinical Trial.
BACKGROUND: We evaluated and compared the effects of sparsentan, a dual endothelin type A (ET(A)) and angiotensin II type 1 receptor antagonist, with those of the angiotensin II type 1 receptor antagonist irbesartan in patients with primary FSGS. METHODS: In this phase 2, rand …
BACKGROUND: We evaluated and compared the effects of sparsentan, a dual endothelin type A (ET(A)) and angiotensin II type 1 receptor antagon …
Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
Hansrivijit P, Cheungpasitporn W, Thongprayoon C, Ghahramani N. Hansrivijit P, et al. BMC Nephrol. 2020 Apr 15;21(1):134. doi: 10.1186/s12882-020-01797-7. BMC Nephrol. 2020. PMID: 32293308 Free PMC article.
BACKGROUND: Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is widely described in children. Clinical evidence in adults is limited. The objective of this study was to determine the treatment outcom …
BACKGROUND: Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is wi …
Recurrence of FSGS after Kidney Transplantation in Adults.
Uffing A, Pérez-Sáez MJ, Mazzali M, Manfro RC, Bauer AC, de Sottomaior Drumond F, O'Shaughnessy MM, Cheng XS, Chin KK, Ventura CG, Agena F, David-Neto E, Mansur JB, Kirsztajn GM, Tedesco-Silva H Jr, Neto GMV, Arias-Cabrales C, Buxeda A, Bugnazet M, Jouve T, Malvezzi P, Akalin E, Alani O, Agrawal N, La Manna G, Comai G, Bini C, Muhsin SA, Riella MC, Hokazono SR, Farouk SS, Haverly M, Mothi SS, Berger SP, Cravedi P, Riella LV. Uffing A, et al. Clin J Am Soc Nephrol. 2020 Feb 7;15(2):247-256. doi: 10.2215/CJN.08970719. Epub 2020 Jan 23. Clin J Am Soc Nephrol. 2020. PMID: 31974287 Free PMC article.
BACKGROUND AND OBJECTIVES: FSGS recurrence after kidney transplantation is a major risk factor for graft loss. However, the natural history, clinical predictors, and response to treatment remain unclear because of small sample sizes and poor generalizability of single-cent …
BACKGROUND AND OBJECTIVES: FSGS recurrence after kidney transplantation is a major risk factor for graft loss. However, the natural history, …
Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis.
Mariani LH, Eddy S, AlAkwaa FM, McCown PJ, Harder JL, Nair V, Eichinger F, Martini S, Ademola AD, Boima V, Reich HN, El Saghir J, Godfrey B, Ju W, Tanner EC, Vega-Warner V, Wys NL, Adler SG, Appel GB, Athavale A, Atkinson MA, Bagnasco SM, Barisoni L, Brown E, Cattran DC, Coppock GM, Dell KM, Derebail VK, Fervenza FC, Fornoni A, Gadegbeku CA, Gibson KL, Greenbaum LA, Hingorani SR, Hladunewich MA, Hodgin JB, Hogan MC, Holzman LB, Jefferson JA, Kaskel FJ, Kopp JB, Lafayette RA, Lemley KV, Lieske JC, Lin JJ, Menon R, Meyers KE, Nachman PH, Nast CC, O'Shaughnessy MM, Otto EA, Reidy KJ, Sambandam KK, Sedor JR, Sethna CB, Singer P, Srivastava T, Tran CL, Tuttle KR, Vento SM, Wang CS, Ojo AO, Adu D, Gipson DS, Trachtman H, Kretzler M. Mariani LH, et al. Kidney Int. 2023 Mar;103(3):565-579. doi: 10.1016/j.kint.2022.10.023. Epub 2022 Nov 25. Kidney Int. 2023. PMID: 36442540 Free PMC article.
Here, an unbiased transcriptomic-driven approach was used to identify molecular pathways which are shared by subgroups of patients with either minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS). Kidney tissue transcriptomic profile-base …
Here, an unbiased transcriptomic-driven approach was used to identify molecular pathways which are shared by subgroups of patients with eith …
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
Wheeler DC, Jongs N, Stefansson BV, Chertow GM, Greene T, Hou FF, Langkilde AM, McMurray JJV, Rossing P, Nowicki M, Wittmann I, Correa-Rotter R, Sjöström CD, Toto RD, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Wheeler DC, et al. Nephrol Dial Transplant. 2022 Aug 22;37(9):1647-1656. doi: 10.1093/ndt/gfab335. Nephrol Dial Transplant. 2022. PMID: 34850160 Free PMC article. Clinical Trial.
BACKGROUND: Despite renin-angiotensin-aldosterone system blockade and immunosuppressive treatment, focal segmental glomerulosclerosis (FSGS) often progresses to kidney failure. ...The primary outcome occurred in 4 (8.9%) and 7 (11.9%) participants r …
BACKGROUND: Despite renin-angiotensin-aldosterone system blockade and immunosuppressive treatment, focal segmental glomerul …
Contributions of Rare Gene Variants to Familial and Sporadic FSGS.
Wang M, Chun J, Genovese G, Knob AU, Benjamin A, Wilkins MS, Friedman DJ, Appel GB, Lifton RP, Mane S, Pollak MR. Wang M, et al. J Am Soc Nephrol. 2019 Sep;30(9):1625-1640. doi: 10.1681/ASN.2019020152. Epub 2019 Jul 15. J Am Soc Nephrol. 2019. PMID: 31308072 Free PMC article.
After excluding such genes, 122 of 363 cases (33.6%) had rare variants in known disease-associated genes, but 30 of 363 controls (8.3%) also harbored rare variants that would be classified as "causal" if detected in cases; applying American College of Medical Genetics filt …
After excluding such genes, 122 of 363 cases (33.6%) had rare variants in known disease-associated genes, but 30 of 363 controls (8.3 …
533 results